NEW CONNECTIONS
Patent Information
- Application Number
- RU2023128517
- Authority / Receiving Office
- RU · RU
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-11-03
- Publication Date
- 2026-09-03
Claims
1. Compound of chemical formula 1-39 2. A method for producing a compound according to claim 1, comprising reacting N,N'-bis-[2-(1H-imidazol-4-yl)ethyl]propanediamide with a corresponding acid selected from the group consisting of hydrochloric, oxalic, tartaric, citric, maleic, methanesulfonic, p-toluenesulfonic and phosphoric acids, in a molar ratio of N,N'-bis-[2-(1H-imidazol-4-yl)ethyl]propanediamide and acid from 5:1 to 1:
5.
3. A pharmaceutical composition for the treatment and / or prevention of inflammation of the mucous membrane of the upper respiratory tract, symptomatic treatment of influenza, acute respiratory viral infections, allergies and allergic rhinitis, containing a compound according to claim 1 in a therapeutically effective amount and at least one pharmaceutically acceptable excipient.
4. The pharmaceutical composition according to claim 3, characterized in that the inflammation of the mucous membrane of the upper respiratory tract is caused by rhinitis.
5. A medicinal product for the treatment and / or prevention of inflammation of the mucous membrane of the upper respiratory tract, containing a compound according to claim 1 or a pharmaceutical composition according to claim 3 or 4.
6. A medicinal product according to paragraph 5, characterized in that said product is a solid dosage form or a liquid dosage form.
7. A medicinal product according to paragraph 5, characterized in that said product is a powder, granule or tablet.
8. The medicinal product according to claim 5, characterized in that said product includes at least one pharmaceutically acceptable excipient.
9. The medicinal product according to paragraph 5, characterized in that the inflammation of the mucous membrane of the upper respiratory tract is caused by rhinitis.
10. Use of a compound according to claim 1 for the treatment and / or prevention of inflammation of the mucous membrane of the upper respiratory tract.
11. Use according to paragraph 10, characterized in that the inflammation of the mucous membrane of the upper respiratory tract is caused by rhinitis, sinusitis or pharyngitis.
12. Use of a compound according to claim 1 for the treatment and / or prevention of cough.